

1 **Treatment with human umbilical cord-derived mesenchymal stem cells**
2 **for COVID-19 patients with lung damage: a randomised, double-blind,**
3 **placebo-controlled phase 2 trial**

4 Lei Shi^{1,2*}, Hai Huang^{3,4*}, Xuechun Lu^{2,5*}, Xiaoyan Yan^{6*}, Xiaojing Jiang⁷, Ruonan Xu¹,
5 Siyu Wang¹, Chao Zhang^{1,2}, Xin Yuan^{1,2}, Zhe Xu^{1,2}, Lei Huang^{1,2}, Jun-Liang Fu^{1,2},
6 Yuanyuan Li¹, Yu Zhang^{8,9}, Weiqi Yao^{9,10}, Tianyi Liu^{2,11}, Jinwen Song^{1,2}, Liangliang
7 Sun^{4,12}, Fan Yang¹³, Xin Zhang^{2,14}, Bo Zhang⁷, Ming Shi¹, Fanping Meng¹, Yanning Song¹,
8 Yongpei Yu⁶, Jiqiu Wen², Qi Li², Qing Mao², Markus Maeurer^{16,17}, Alimuddin Zumla¹⁸,
9 Chen Yao^{6#}, Wei-Fen Xie^{4,15#}, Fu-Sheng Wang^{1,2#}

10

- 11 1. Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General
12 Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
13 2. Wuhan Huoshenshan Hospital, Wuhan, China.
14 3. Department of Respiratory, Changzheng Hospital, Second Military Medical University,
15 Shanghai, China.
16 4. Optical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan,
17 China.
18 5. Department of Hematology, Second Medical Center of Chinese PLA General Hospital,
19 Beijing, China.
20 6. Peking University Clinical Research Institute, Peking University First Hospital, Beijing,
21 China.
22 7. Department of Infectious Disease, General Hospital of Central Theater Command,
23 Wuhan, China.

- 24 8. VCANBIO Cell & Gene Engineering Corp., Ltd. Tianjin, China.
- 25 9. National Industrial Base for Stem Cell Engineering Products, Tianjin, China.
- 26 10. Department of Hematology, Union Hospital, Tongji Medical College, Huazhong
27 University of Science and Technology, Wuhan, China.
- 28 11. Key Laboratory of Cancer Center, Fifth Medical Center of Chinese PLA General
29 Hospital, Beijing, China.
- 30 12. Department of Endocrinology and Metabolism, Changzheng Hospital, Second Military
31 Medical University, Shanghai, China.
- 32 13. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong
33 University of Science and Technology, Wuhan, China.
- 34 14. Nursing Department, Fifth Medical Center of Chinese PLA General Hospital, Beijing,
35 China.
- 36 15. Department of Gastroenterology, Changzheng Hospital, Second Military Medical
37 University, Shanghai, China.
- 38 16. Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.
- 39 17. I Med Clinic, University of Mainz, Mainz, Germany.
- 40 18. Center for Clinical Microbiology, Division of Infection and Immunity, University
41 College London, and UCL Hospitals NIHR Biomedical Research Centre, London, UK
- 42 * Drs. Lei Shi, Hai Huang, Xuechun Lu and Xiaoyan Yan contributed equally to this
43 article.

44 ***Correspondence to:***

45 # Prof. Fu-Sheng Wang, Department of Infectious Diseases, Fifth Medical Center of
46 Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases,

47 No.100 Western 4th Ring Road, Beijing 100039, China. fswang302@163.com

48 # Prof. Wei-Fen Xie, Department of Gastroenterology, Changzheng Hospital, Second

49 Military Medical University, 415 Fengyang Road, Shanghai, 200003, China.

50 weifexie@medmail.com.cn

51 # Prof. Chen Yao, Peking University Clinical Research Institute, Peking University First

52 Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China

53 yaochen@hsc.pku.edu.cn

54 **Abstract** (250 words)

55 **BACKGROUND**

56 Treatment of severe Corona Virus Disease 2019 (COVID-19) is challenging. We performed
57 a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal
58 stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our
59 phase 1 data.

60 **METHODS**

61 In this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe
62 COVID-19 patients with lung damage. They were randomly assigned to receive either
63 UC-MSCs (4×10^7 cells per infusion) or placebo on day 0, 3, and 6. The primary endpoint
64 was an altered proportion of whole lung lesion volumes from baseline to day 28. Other
65 imaging outcomes, 6-minute walk test, maximum vital capacity, diffusing capacity, and
66 adverse events were recorded and analysed.

67 **RESULTS**

68 100 COVID-19 patients were finally recruited to receive either UC-MSCs (n = 65) or
69 placebo (n = 35). UC-MSCs administration exerted numerical improvement in whole lung
70 lesion volume from baseline to day 28 compared with the placebo (the median difference
71 was -13.31%, 95%CI -29.14%, 2.13%, P=0.080). UC-MSCs significantly reduced the
72 proportions of solid component lesion volume compared with the placebo (median
73 difference: -15.45%; 95% CI -30.82%, -0.39%; P=0.043). The 6-minute walk test showed
74 an increased distance in patients treated with UC-MSCs (difference: 27.00 m; 95% CI 0.00,
75 57.00; P=0.057). The incidence of adverse events was similar in the two groups.

76 **CONCLUSIONS**

77 UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19
78 patients with lung damage. (Funded by The National Key R&D Program of China and

79 others. ClinicalTrials.gov number, NCT04288102.)

80 **Introduction**

81 The Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome
82 coronavirus 2 (SARS-CoV-2) infection,¹ causes substantial damage to lungs, ranging from
83 mild respiratory illness to severe acute respiratory syndrome, and death,²⁻⁴ Dysregulated
84 immune responses of both the innate and adaptive immune systems are associated with
85 disease severity, lung damage and long term functional disability.⁵⁻⁸ There are currently no
86 prophylactic vaccines or effective antiviral agents available to treat COVID-19 and
87 management of COVID-19 patients remains largely symptomatic and supportive therapy.⁹
88 Therefore, there is an urgent need for safe and alternative therapeutic options to mitigate
89 inflammatory organ injury. Currently ongoing clinical trials of immunotherapeutic
90 approaches include convalescent plasma therapy, monoclonal antibodies against
91 interleukin-6, and cellular therapies.¹⁰⁻¹² Mesenchymal stem cells (MSC) are
92 non-hematopoietic cells with immune modulatory, regenerative, and differentiation
93 properties.¹³ MSC treatment reduced the pathological changes of the lung and inhibits the
94 cell-mediated immune-inflammatory response induced by the influenza virus in animal
95 models and clinical trials.^{14 15} The safety and potential efficacy of MSC have also been
96 evaluated in the patients with acute respiratory distress syndrome (ARDS).¹⁶⁻¹⁹ The
97 immunomodulatory and regenerative properties of MSCs offer potential cellular
98 therapeutic option for limiting lung damage in patients with COVID-19 and require
99 evaluation in randomized controlled. In a phase 1 trial we previously demonstrated that
100 intravenous transfusions of human umbilical cord (UC)-MSCs in patients with moderate
101 and severe COVID-19 were safe and well tolerated (NCT04252118).²⁰ We now report
102 results of a randomized, double-blind, placebo-controlled trial performed at 2 medical
103 centers in Wuhan, China, evaluating the safety and efficacy of intravenous treatment with
104 UC-MSCs in severe COVID-19 patients with lung damage.

105 **Methods**

106 **Design**

107 We conducted a randomized, placebo-controlled, double-blind phase 2 trial
108 (ClinicalTrials.gov: NCT04288102). The study was done between 5 March 2020 and 28
109 March 2020. Ethical approval was obtained from the institutional review boards of each
110 participating hospital. Written informed consent was obtained from all the enrolled patients
111 or their legal representatives if they were unable to provide consent. The clinical protocol
112 and statistical analysis plan are available in Supplement 1 and Supplement 2.

113

114 **Inclusion and Exclusion Criteria**

115 Hospitalised patients with severe COVID-19 with laboratory-confirmed SARS-CoV-2
116 infection by reverse transcription polymerase chain reaction (RT-PCR) were screened.
117 Patients were eligible if they met any of the following criteria:1) severe COVID-19
118 diagnosed after onset of disease; 2) chest computed tomography (CT) imaging confirmed
119 pneumonia combined with lung damage. The illness severity of COVID-19 was evaluated
120 in accordance with Guidelines issued by the National Health Commission of China
121 (version 7.0).²¹ Briefly, patients with any of the following conditions but without invasive
122 ventilation, shock or other organ failure (need organ support therapy) were considered as
123 severe cases: 1) dyspnoea (respiratory rate \geq 30 times/min); 2) oxygen saturation of 93%
124 or lower on room air; 3) arterial oxygen partial pressure (PaO₂)/fraction of inspired oxygen
125 (FiO₂) \leq 300 mmHg; 4) pulmonary imaging showing that the foci progressed by > 50% in
126 24-48 hours. The exclusion criteria included patients with shock or COVID-19 combined

127 with any one of other organ failures, those who received invasive ventilation, or patients
128 with any malignant tumour, pregnancy or breastfeeding, or co-infection of other pathogens.

129 **Randomization and masking**

130 Eligible patients were randomly assigned in a 2:1 ratio to receive either UC-MSCs or the
131 placebo, in addition to standard care, using an interactive web response management
132 system (IWRS). A permuted-block randomisation sequence that was stratified by the trial
133 sites was generated and uploaded to the system. Patients, investigators, and outcome
134 assessors (independent central imaging reviewers) were all blinded to the treatment
135 allocation. Blinding was also ensured by the product marking, with the UC-MSCs and the
136 placebo having a similar appearance and packaging.

137 A barcode-based product management system (Product Identification Authentication
138 and Tracking System, PIATS) was introduced in this study to manage and track the study
139 products logistics, e.g., preparation, packaging, shipping, storage, and clinical
140 administration to the patients. The application of PIATS could realize the blind label
141 processing by non-informative unique barcodes of the clinical study drug. The
142 concealment of the randomisation sequence could be ensured using PIATS and IWRS.

143 **UC-MSCs preparation, dosage, and safety monitoring**

144 UC-MSCs were prepared by VCANBIO Cell & Gene Engineering Corp, Tianjin, China.
145 Briefly, the MSCs were obtained according to the method described in our previous
146 study.²⁰ The UC-MSCs used in this study came from one umbilical cord of full-term
147 deliveries (after consultation with the parents of UC donor). The Wharton's Jelly (WJ)
148 tissues were cut into approximately 2 mm³ pieces from cord tissue and planted upside
149 down on tissue culture flasks (75 cm²) cultured in DMEM/F12, supplemented with fetal
150 bovine serum (10% FBS, BI, Israel) at 37°C with 5% CO₂. The adherent cells were
151 detached with 1×TrypLE (GIBCO, USA) and then re-plated at a density of approximately

152 $6-8 \times 10^3$ cells/cm² for further expansion. Master cell bank at passage 2 and working cell
153 bank at passage 4 were set separately. A homogenous population of cultured cells at
154 passage 5 were prepared as UC-MSc product. The culture cells were identified by the
155 minimal criteria suggested by International Society for Cellular Therapy (ISCT): (1) plastic
156 adherent under tissue culture flask; (2) >95% of the cell population expressed CD105,
157 CD73 and CD90, and these cells were lack expression (<2% positive) of CD45, CD34,
158 CD11b, CD19 and HLA-DR as measured by flow cytometry (BD, FACS Calibur, USA); (3)
159 differentiation potential into osteoblasts, adipocytes and chondroblasts under standard in
160 vitro differentiating conditions. For each individual MSC batch, cell viability was
161 examined using both trypan blue and 7-AAD/Annexin V staining by flow cytometry after
162 preparation in Tianjin and before intravenous transfusion in Wuhan, respectively
163 (Supplement 3). The cell product has been certified by the National Institutes for Food and
164 Drug Control of China.

165 The UC-MSc product was an almost colourless suspension containing 4.0×10^7
166 MSCs in a volume of 100 ml/bag. The placebo had the same medium and appearance in
167 packaging and suspension, but without the MSCs. After preparation, both the MSC and
168 placebo products were shipped to the clinical facilities in an ice box with a real-time
169 monitoring and alarm device for temperature and location to ensure the best storage
170 conditions (8–12 °C). Shipping of cell products by express railway from Tianjin to Wuhan
171 took less than 6 hours.

172 The treatment dose was 4.0×10^7 cells for each procedure, and three procedures were
173 carried out for each patient on day 0, 3, and 6 after randomisation. Infusion was started
174 with a standard blood filter tubing set with a pore size of 170 µm. Under
175 electrocardiographic monitoring, the cell product was infused by gravity within 60 min.
176 We also monitored continuous pulse oximetry as well as patient's physical signs including

177 body temperature, pulse, skin color, respiration, and blood pressure during the infusion
178 period and up to 30 min after infusion.

179 The incidence and nature of all adverse events were reviewed and assessed by the
180 investigators to determine whether they were related to the administration of the study
181 product. Methods for data collection and in-study measurements are described in detail in
182 Supplement 1.

183 **Imaging and clinical outcomes**

184 All patients underwent high-resolution chest CT examination at baseline, day 10, and day
185 28. The primary outcome was gauged as a change in the total lesion proportion (%) of the
186 whole lung volume from baseline to day 28, as measured by chest CT. It was defined as
187 (total lesion proportion of the whole lung volume at day 28–total lesion proportion of the
188 whole lung volume at baseline) / total lesion proportion of the whole lung volume at
189 baseline. The secondary imaging outcomes were a change in the total lesion proportion (%)
190 of the whole lung volume from baseline to day 10, a change in solid component and
191 ground-glass lesion proportion from baseline to day 10, 28, and change in lung
192 densitometry at day 10, 28. Lung lesions were evaluated by using the changes in
193 high-resolution chest CT images and measured by centralised imaging interpretation based
194 on both lung radiologist analyses and imaging software. The imaging data were derived
195 from a software-assisted lung volumetry and densitometry procedure (Supplement 1).

196 Clinical outcomes within 28 days included 6-minute walk test (6-MWT), status of
197 oxygen therapy maximum forced vital capacity (VC_{max}), diffusion lung capacity for carbon
198 monoxide (DL_{CO}), modified Medical Research Council Dyspnoea Scale (mMRC), changes
199 in absolute lymphocyte counts and subsets, as well as plasma cytokine and chemokine
200 levels. Safety evaluation included adverse events and all-cause mortality. Detailed

201 definitions and assessment procedures are described in Supplement 1.

202 **Statistical analysis**

203 This study was designed as a phase 2 clinical trial. The limited efficacy information of the
204 medication in patients with COVID-19 and the exploratory nature of this study meant that
205 the original target sample size was not justified by statistical calculation and was set as 45
206 patients, with an allocation ratio of 2:1. Minimal serious adverse events were observed in
207 our phase 1 trial; therefore, the sample size was expanded to 90, and finalized at 101, to
208 obtain more data from this study. Sample size adjustments were made in a manner that
209 maintained the double-blind status of this study and were approved by the institutional
210 review boards of the two participating hospitals.

211 There were no pre-defined hypotheses made in this study; therefore, we focused on
212 description instead of inference for statistical analyses: all statistical tests, confidence
213 intervals, and *P*-values were used for exploration, not for inference. For primary outcome
214 analysis – the change in the total lesion proportion (%) of the whole lung volume from
215 baseline to day 28 and the difference between the UC-MSD and placebo groups was tested
216 using wilcoxon rank sum test and the median differences were calculated using the
217 Hodges–Lehmann estimation (It was also applied to other secondary outcomes which were
218 not in accordance with normal distribution.). Six category scale and MMRC dyspnea score
219 were calculated by using ordinal logistic regression model. The modified intention-to-treat
220 (mITT) population was considered as the primary analysis population and safety analysis
221 was done in all patients who started their assigned treatment. If the patient missed a chest
222 CT scan, the last scan's results were carried forward to the missing visit for primary
223 endpoints in the mITT analysis. Other missing values of secondary endpoints and
224 per-protocol analyses were not imputed. Statistical analyses were performed using SAS
225 software, version 9.4 (Cary, NC, USA). The figures were generated using GraphPad Prism

226 7 software (GraphPad Inc., La Jolla, CA, USA).

227

228 **Results**

229 **Study Population**

230 From March 5, 2020, to March 28, 2020, a total of 288 patients were screened at two
231 hospitals in Wuhan city. The majority of severe hospitalized COVID-19 patients were at
232 the convalescent stage and some of them were with progression stage. Among them, 101
233 eligible patients previously diagnosed as severe COVID-19 type, being referred as the ITT
234 population, were randomized in a 2:1 ratio (66 to the UC-MSD group and 35 to the placebo
235 group). One patient in the treatment group withdrew her previously written informed
236 consent after randomisation and did not receive UC-MSD infusion. Therefore, 65 and 35
237 patients were treated with UC-MSD or placebo, respectively, who were defined as the
238 modified intention-to treat (mITT) population, as shown in Figure 1. Some patients missed
239 the follow-up check on day 28 or received the examination outside of the follow-up
240 window; therefore, the per-protocol (PP) population included 49 patients in the MSD group
241 and 25 patients in the placebo group (Supplement 4).

242 **Baseline characteristics**

243 The baseline characteristics were highly consistent between the two groups of patients
244 in the mITT population (Table 1). Briefly, baseline age, sex, BMI, time from symptom
245 onset, distribution of comorbidities, concomitant medication, and lesion proportions
246 assessment from chest CT were matched in the two groups. The median time from
247 symptoms onset to study baseline was 45.00 (39.00, 51.00) days in the MSD group and
248 47.00 (41.00, 53.00) days in the placebo group. The most common comorbidity was
249 hypertension, followed by diabetes. The majority of the patients at baseline has a clinical
250 status of category 2 or category 3, as shown by evaluation of the Six Category Scale. In
251 detail, there were 14 (21.54%), 50 (76.92%), and 1 (1.54%) patients in category 2, 3, and 4,

252 respectively, at baseline in the MSC group; and 10 (28.57%), 25 (71.43%), 0 (0.00%) in
253 category 2, 3, and 4, respectively, in the placebo group. There were no statistical
254 differences in laboratory results, including D-dimer, interleukin-6 (IL-6), and C-reactive
255 protein (CRP) between the two groups.

256 **Imaging and clinical outcomes**

257 To evaluate the difference in the primary endpoint and parts of the secondary endpoints, we
258 analysed the changes in high-resolution chest CT images and measured the lesions by
259 using centralised imaging interpretation based on the evaluation of both radiologist
260 analyses and lung imaging artificial intelligence software. Through comparison of the
261 Hodges-Lehmann estimator of the total lesion proportion (%) of the whole lung volume,
262 the median change was -19.40% (95% CI, -53.40%, -2.62%) in the MSC group, and -7.30%
263 (95%CI, -46.59%, 19.12%) in the placebo group on day 28 from baseline, yielding a
264 difference of -13.31% (95% CI, -29.14%, 2.13%, $P= .080$) (Figure 2, Table 2, Supplement
265 5). Interestingly, in the evaluation of the solid component lesions as a specific lesion type,
266 we found that the median change from baseline to day 28 were -57.70% (95%CI, -74.95%,
267 -36.56%) and -44.45% (95% CI, -62.24%, -8.82%) in the MSC and placebo groups,
268 respectively, leading to a significant difference between the MSC group and placebo group
269 (95% CI -30.82%, -0.39%, $P= .043$). We also observed decrease in the ground-glass
270 lesions in the MSC group than the placebo group, although the difference was not
271 statistically significant. To exclude the effect of missing data on the outcomes of the above
272 results in some mITT cases, we further analysed the PP population. Almost identical results
273 between the two groups were obtained, as shown in Supplement 6 and 7.

274 To compare the restoration of lung function and integrated reserve capability among
275 the two groups of patients, we examined the 6-MWT on the 28th day after the onset of
276 treatment and found that 6-minute walking distance was longer in the MSC group (median

277 420.00 meters [interquartile range (IQR) 392.00,465.00]) than in the placebo group
278 (median 403.00 meters [IQR 352.00,447.00]) with a 95% CI of 0.00–57.00 ($P= .057$, Table
279 2). Other parameters including VCmax and DLco, the six-category scale, status of oxygen
280 therapy and mMRC dyspnoea score were similar between the two groups (Table 2). In
281 addition, there was no significant difference in the subsets of peripheral lymphocyte counts
282 (CD4+ T cells, CD8+ T cells, B cells, NK cells) and plasma markers between the two
283 groups (Supplement 8).

284 **Post Hoc Analyses**

285 We have established five models in three analysis data sets (mITT, PPS and ITT) for
286 sensitivity analyses of primary end point (Supplement 9). The five models included:
287 treatment group factor was included in model 1, treatment group and center factors were
288 included in model 2 as fixed effects, and treatment group, baseline and center factors were
289 included as fixed effects in model 3, center factor was included as random effect, treatment
290 group factor was included as fixed effects in model 4, center factor was included as
291 random effect, treatment group and baseline factors were included as fixed effects in model
292 5. The conclusions of all models were consistent with those of univariate analysis.

293 **Safety**

294 The incidence of adverse events reported during the study was similar in the MSC group
295 (55.38%) and the placebo group (60%) (Table 3). The most common adverse event in the
296 MSC group was an increase in lactic acid dehydrogenase (13.85%), compared with 20% in
297 the placebo group; a 10.77% elevation of serum alanine aminotransferase compared with
298 11.43% in the placebo group; a 9.23% increase in hypokalaemia compared with 2.86% in
299 the placebo group; a 7.69% increase in aspartate aminotransferase compared with 11.43%
300 in the placebo group; and a 7.69% increase in hyperuricemia compared with 8.75% in the

301 placebo group. Only one case experienced a grade 3 adverse event (pneumothorax) in the
302 MSC group, which recovered spontaneously under conservative treatment. There were few
303 other adverse events at grade 1 or 2 in both groups. All adverse events during the
304 observation period were judged by the site investigators and found to be unrelated to
305 UC-MSC intervention. No deaths were observed in this trial.

306 **Discussion**

307 Whilst several trials of the therapeutic use of MSCs for patients with COVID-19 have been
308 registered at Clinicaltrial.gov, there are no data available to date from randomized
309 placebo-controlled clinical trials yet. This is the first report of a double-blind, randomized,
310 and controlled phase 2 trial, in COVID-19 patients with lung damage. Our data found that
311 UC-MSC administration was safe and well tolerated and exerted a trend of improvement in
312 whole lung lesion for COVID-19 patients. More interestingly, UC-MSC medication
313 significantly increased the resolution of lung solid component lesions compared with the
314 placebo. The data from the 6-MWT data show an improved restoration of the integrated
315 reserve capability in the UC-MSC-treated patients. These findings indicate that the use of
316 UC-MSC as adjunctive therapy to standard of care treatment for patients with COVID-19
317 is a viable option. Recently, MSCs have been approved conditionally by the US-FDA
318 under what is known as ‘expanded access compassionate use’ for COVID-19 patients. A
319 phase 3 trial is now required to further evaluate effects on mortality and long term
320 pulmonary disability, and to determine the underlying mechanisms of UC-MSC treatment
321 for COVID-19 disease.²²

322 COVID-19 is characterized by pathological lung changes in both the parenchyma
323 and interstitium², including ground glass opacity, solid component, traction bronchiectasis,

324 reticulation, and thickening of the bronchovascular bundles, as imaged using chest CT²³.
325 Notably, the improvement of pulmonary lesions, especially the improvement of pulmonary
326 interstitial lesions, directly affects the recovery of lung function and the remission of
327 clinical symptoms.²⁴ The outbreak of COVID-19 occurred in China in January and early
328 February, and was basically brought under control in March. As enrolment ensured, many
329 severe hospitalized COVID-19 patients were at the convalescent stage and some of these
330 patients in the progression stage, which presented a challenge to explore clinical
331 improvement. Considering lung damage was still a common characteristic in these patients
332 at convalescent phase which affected their recovery and life quality, we modified the
333 primary outcome to the change in the total lesion proportion (%) of the whole lung volume
334 as measured by CT from baseline to day 28. The patients enrolled in this study were all
335 previously diagnosed as severe types, with a longer disease course and older age,
336 compared with the recent studies.^{25,26} In particular, all the patients suffered from serious
337 pulmonary damage and needed oxygen inhalation support during the course of disease. Our
338 current trial showed that UC-MSCs therapy improved the resolution of the whole lung
339 damage size, as detected by CT scanning, particularly the solid component lesions. This
340 finding indicated that UC-MSC administration has a therapeutic benefit for patients with
341 COVID-19, even in the convalescent stage. It is known that the solid component lesions in
342 the lung include the interstitial fibrosis. Thus, the improvements of solid component lesions
343 might also imply the alleviation of lung fibrosis.

344 The 6-MWT has been used to evaluate patients suffering from a variety of
345 cardiopulmonary diseases. The results reflect the integrated reserve capability of complex
346 physiology, involving the pulmonary and cardiovascular systems, and neuromuscular
347 circulation²⁷. In this trial, the 6-MWT was numerically, but not statistically, improved in
348 the MSC group compared with that in the placebo group. Given that there was no

349 significant difference in cardiovascular diseases between the two groups and no
350 cerebrovascular diseases in both groups at baseline, the findings from the 6-MWT data
351 imply that capacity for aerobic exercise was potentially improved in the UC-MSCs group.

352 It is hypothesized that the beneficial effect of MSC treatment for patients with severe
353 COVID-19 is mediated via reduction of pro-inflammatory cytokines, that jointly mediate
354 immune pathology and worsen clinical COVID-19 outcomes.^{7,28-30} Cytokines such as
355 serum IL-6 are considered as biologically relevant biomarkers associated with disease
356 progression of COVID-19. In this study, UC-MSC infusion did not result in a significant
357 reduction in the duration of oxygen therapy, mMRC, cytokine, or chemokine levels, which
358 might be in part attributed to the status of the enrolled population, since most of them were
359 not in the acute progressive stage. Other mechanisms of actions have to be explored for
360 MSCs that are measurable in the systemic circulation. We could not, however, measure the
361 local, i.e. intrapulmonary, effects of MSC delivery. It could very well be that the local
362 MSC-mediated effects were not measurable in the systemic circulation, a similar scenario
363 as in MSC treatment of patients with corticosteroid-resistant graft-versus-host-disease
364 (GVHD).

365 In our trial, a total of three doses of 4×10^7 UC-MSCs were transfused for each
366 patient. No MSC-related predefined haemodynamic or respiratory adverse events were
367 observed. The incidences of adverse events were similar between the MSC group and the
368 placebo group. Only one patient in the MSC group suffered a pneumothorax that was
369 judged to be unrelated to UC-MSC medication. No patient died during the follow-up period.
370 The safety profile of the UC-MSCs confirms the results of our previous phase 1 trial²⁰ and
371 other MSC studies.^{31,32} These data suggested that UC-MSC therapy was well tolerated and
372 very safe. In view of the ongoing clinical trials with higher dose of MSCs used in other
373 groups in China, America, and Europe,²² more safety data are expected in the near future.

374 There were several operational limitations to our study. A larger sample size could
375 have improved efficacy analyses. According to management guidelines issued by the
376 Chinese National Health Commission (7th edition),²¹ patients with COVID-19 require
377 further centralized isolation for 14 days after discharge. In this setting, some of the patients
378 missed the follow-up data at day 28, but they did receive a follow-up check around 7–10
379 days after the 28-day follow-up window. Importantly, our PP population analysis also
380 revealed similar results compared with mITT population analysis. Whether the cell dosage,
381 interval duration, and cycles of UC-MSD medication were the best regimen for patients
382 with severe COVID-19 were not fully investigated in this study.

383 To the best of our knowledge, this is the first randomized, double-blind,
384 placebo-controlled trial evaluating the safety and preliminary efficacy of UC-MSDs as a
385 potential treatment for patients with COVID-19 with lung damage, even at the
386 convalescent stage. UC-MSD administration was safe and accelerated resolution of lung
387 solid component lesions and improvement in the integrated reserve capability after
388 UC-MSD administration. UC-MSDs treatment offers a safe and potentially effective
389 therapeutic approach for COVID-19 patients with lung damage. A phase 3 trial is required
390 to further evaluate effects on preventing long-term pulmonary disability, reducing
391 mortality and determining the underlying mechanisms of UC-MSD treatment for
392 COVID-19 disease.

393 **Contributions**

394 FSW ideated and led the study. FSW, WFX, CY and LS designed the study and developed
395 the protocol. LS, HH, XCL, XY, ZX, LH, JLF and LLS were responsible for study
396 enrolment. LS, XCL, XY, ZX, LH, JLF were responsible for acquisition, analysis, and
397 interpretation of data. YZ, WQY, CZ, TYL and JWS were responsible for biorepository
398 management and biomarker analyses. All authors made substantial contributions to
399 conduct and coordination of trial and had regular discussions on progress of the study. CY,
400 YXY and YPY contributed to statistical analysis. LS, RNX and CZ wrote the initial
401 manuscript draft, and FSW, WFX, MM and AZ critically revised the manuscript. All
402 authors edited, read and approved the final version before submission.

403 **Funding**

404 This trial was supported by The National Key R&D Program of China (2020YFC0841900,
405 2020YFC0844000, 2020YFC08860900); The Innovation Groups of the National Natural
406 Science Foundation of China (81721002); The National Science and Technology Major
407 Project (2017YFA0105703). The funder of the study had no role in the study design, data
408 collection, data analysis, data interpretation, or writing of this report. The corresponding
409 author had full access to all the data in the study and had final responsibility for the
410 decision to submit for publication.

411 **Competing interests**

412 All authors declare no competing interests.

413 **Ethical approval**

414 This study was approved by the Clinical Trial Ethics Committee of Fifth Medical Cente,
415 Chinese PLA General Hospital (2020-013-D), the Medical Ethics Committee of Wuhan
416 Huoshenshan Hospital(HSSLL004), the Medical Ethics Committee of Maternal and Child
417 Hospital of Hubei Province(2020IEC001).Written informed consent was obtained from all
418 the enrolled patients or their legal representatives if they were unable to provide consent.

419 **Data sharing**

420 After approval from the Human Genetic Resources Administration of China, this trial data
421 can be shared with qualifying researchers who submit a proposal with a valuable research
422 question. A contract should be signed.

423 **Acknowledgements**

424 F-S.W, C.Z, M.M., and A.Z. are founder members of the Global Cancer and Infectious
425 Diseases consortium for Host-Directed therapies (<https://www.fchampalimaud.org/covid19/aci/>)

426 **Additional Contributions**

427 We thank Drs. Sibing Zhang, Dixiong Xu, Fangguo Dai and Bin Liu for logistic support
428 and valuable suggestions to the clinical study. We also thank Fang Lian, Baoqiang Fu,
429 Yingying Gao and Yan Zhang for their excellent work in follow-up of all enrolled patients.
430 We thank randomization system provider (Chengdu Cims-medtech), PIATS provider
431 (Alibaba Health Technology) and academic secretaries (Yufeng Guo, Hairui Si, Lvshuai
432 Huang, Junqing Luan) for their services. We also thank the People's Government of
433 Wuhan Municipality for the help in organizing the follow-up work.

434

435 **References**

- 436 1. WHO. Coronavirus disease (COVID-2019) situation reports. 2020. at
437 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>)
- 438 2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute
439 respiratory distress syndrome. *Lancet Respir Med* 2020;8:420-2.
- 440 3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
441 coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
- 442 4. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with
443 poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*
444 2020;18:844-7.
- 445 5. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients
446 reveals distinct immunotypes with therapeutic implications. *Science* 2020.
- 447 6. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune
448 perturbations associated with severe COVID-19. *Sci Immunol* 2020;5.
- 449 7. Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and
450 severe cases of COVID-19. *Nat Commun* 2020;11:3410.
- 451 8. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the
452 Science. *Immunity* 2020;52:910-41.
- 453 9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
454 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in
455 the New York City Area. *JAMA* 2020.
- 456 10. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with
457 Covid-19 - Preliminary Report. *N Engl J Med* 2020.
- 458 11. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to
459 Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A
460 Randomized Clinical Trial. *JAMA* 2020.
- 461 12. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single
462 center experience. *J Med Virol* 2020;92:814-8.

- 463 13. Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and
464 Therapeutic Opportunities. *Cell Stem Cell* 2018;22:824-33.
- 465 14. Chan MC, Kuok DI, Leung CY, et al. Human mesenchymal stromal cells reduce
466 influenza A H5N1-associated acute lung injury in vitro and in vivo. *Proc Natl Acad Sci*
467 *U S A* 2016;113:3621-6.
- 468 15. Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treating acute
469 respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a
470 hint for COVID-19 treatment. *Engineering (Beijing)* 2020.
- 471 16. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal
472 stromal cells for moderate to severe acute respiratory distress syndrome (START
473 study): a randomised phase 2a safety trial. *Lancet Respir Med* 2019;7:154-62.
- 474 17. Simonson OE, Mougiakakos D, Heldring N, et al. In Vivo Effects of Mesenchymal
475 Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.
476 *Stem Cells Transl Med* 2015;4:1199-213.
- 477 18. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of
478 ARDS: a phase 1 clinical trial. *Lancet Respir Med* 2015;3:24-32.
- 479 19. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome
480 with allogeneic adipose-derived mesenchymal stem cells: a randomized,
481 placebo-controlled pilot study. *Respir Res* 2014;15:39.
- 482 20. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell
483 therapy in patients with COVID-19: a phase 1 clinical trial. *Signal Transduct Target*
484 *Ther* 2020;5:172.
- 485 21. New coronavirus pneumonia prevention and control program (7th edn). at
486 <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtm>
487 ml.)
- 488 22. Zumla A, Wang FS, Ippolito G, et al. Reducing mortality and morbidity in patients
489 with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal
490 (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular
491 host-directed therapies. *Int J Infect Dis* 2020;96:431-9.

- 492 23. Yang Q, Liu Q, Xu H, Lu H, Liu S, Li H. Imaging of coronavirus disease 2019: A
493 Chinese expert consensus statement. *Eur J Radiol* 2020;127:109008.
- 494 24. Antoine M, Mlika M. Interstitial Lung Disease. StatPearls. Treasure Island
495 (FL)2020.
- 496 25. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use,
497 and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals:
498 an observational study. *Lancet Respir Med* 2020;8:853-62.
- 499 26. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in
500 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
501 prospective observational cohort study. *BMJ* 2020;369:m1985.
- 502 27. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test.
503 *Am J Respir Crit Care Med* 2002;166:111-7.
- 504 28. Chen B, Tian EK, He B, et al. Overview of lethal human coronaviruses. *Signal*
505 *Transduct Target Ther* 2020;5:89.
- 506 29. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. *Immunity*
507 2020.
- 508 30. Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses
509 in patients with COVID-19. *Nat Immunol* 2020.
- 510 31. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells
511 Improves the Outcome of Patients with COVID-19 Pneumonia. *Aging Dis*
512 2020;11:216-28.
- 513 32. Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the
514 treatment of patients with severe COVID-19. *Front Med* 2020.
- 515

516 **Figure 1: Trial profile**

517 ITT = intention-to treat population. mITT = modified intention-to treat population

518

519 **Figure 2. Decline in total and solid component lesion proportion (%) between the**
520 **umbilical cord-mesenchymal stem cell (UC-MSc) group and placebo group at 28**
521 **days.**

522 A. Panel A shows the between-group median difference in the change in total lesion
523 proportion (%) and solid component lesion proportion (%) of the whole lung volume
524 from baseline to day 28. I bars indicate the 95%CI described by Hahn and Meeker
525 (1991).

526 B. Panel B shows box plots of the change in the total lesion proportion (%) and solid
527 component lesion proportion (%) of the whole lung volume from baseline to day 28. Q1
528 denotes the first quartile, and Q3 the third quartile. I bars indicate the minimum and
529 maximum.

530 C. Panel C shows the mean absolute change from baseline in the total lesion proportion (%)
531 and solid component lesion proportion (%) of the whole lung volume. I bars indicate the
532 standard error.

533 **Table 1: Baseline patient characteristics.**

	UC-MSc group (n = 65)	Placebo group (n = 35)
Age, years	60.72(9.14)	59.94(7.79)
Sex – no. (%)		
Men	37 (56.92%)	19 (54.29%)
Women	28 (43.08%)	16 (45.71%)
BMI (Body Mass Index), Kg/m ² *	24.71(3.19)	25.01(3.12)
Time from symptom onset to baseline, days	45.00(39.00,51.00)	47.00(41.00,53.00)
Any comorbidities	34 (52.31%)	18 (51.43%)
Hypertension	17 (26.15%)	10 (28.57%)
Diabetes	12 (18.46%)	5 (14.29%)
Chronic bronchitis	2(3.08%)	3(8.57%)
Chronic obstructive pulmonary disease	2(3.08%)	0(0.00%)
Concomitant medication		
Antiviral drugs	32 (49.23%)	20 (57.14%)
Antibiotics	27 (41.54%)	12 (34.29%)
Corticosteroids	13 (20.00%)	9 (25.71%)
Lesion proportion (%): total lesion volume (in cm ³) / whole lung volume (in cm ³)	26.31(11.62,38.42)	27.98(11.57,44.14)
Solid component lesion proportion (%): Solid component lesion volume (in cm ³) / whole lung volume (in cm ³)	2.59(0.69,5.20)	2.52(0.77,4.91)
Six-category scale		
2-Hospitalized, not requiring supplemental oxygen	14 (21.54%)	10 (28.57%)
3-Hospitalized, requiring supplemental oxygen	50 (76.92%)	25 (71.43%)
4-Hospitalized, on noninvasive ventilation or high flow oxygen devices	1 (1.54%)	0 (0.00%)
White blood cell count* (10 ⁹ /L)	5.70(5.00,6.60)	5.80(5.00,6.80)
Lymphocyte count (10 ⁹ /L)	1.39(1.19,1.80)	1.47(1.24,1.84)
CD4 T cells (/μl) †	641.00(482.00,760.00)	734.00(502.00,1031.00)
CD8 T cells (/μl) †	371.00(275.00,520.00)	401.00(307.00,593.00)

B cells (/μl) †	148.50(99.60,251.00)	148.50(94.70,248.00)
NK cells (/μl) †	233.50(151.00,393.00)	197.50(136.00,309.00)
Neutrophil count (10 ⁹ /L)	3.48(2.91,4.32)	3.83(2.85,4.48)
Platelet count (10 ⁹ /L)	214.00(174.00,255.00)	210.00(176.00,247.00)
Hemoglobin (g/L)	122.68 (14.44)	124.26 (11.83)
D-dimer (mg/L) ‡	0.58 (0.36,1.11)	0.56 (0.31,1.12)
IL-6 (pg/ml) §	7.86(5.63,9.84)	8.76(6.54,11.77)
CRP(mg/L) ¶	1.95(0.84,3.53)	1.38(0.68,2.26)
SARS-CoV-2 test result		
SARS-Cov-2 IgG positive	63 (100.00%)	34 (100.00%)
SARS-Cov-2 IgM positive	58 (92.06%)	32 (94.12%)
SARS-Cov-2 nucleic acid detection positive	47(72.31%)	20(57.14%)

534 Data are median (interquartile range (IQR)), n (%), or mean (SD)

535 * BMI values were available for 59 patients in the UC-MS group and 33 patients in the placebo group.

536 † CD4, CD8, CD19, and CD56 values were available for 62 patients in the UC-MS group and 34 patients in the placebo
537 group.

538 ‡ D-dimer values were available for 55 patients in the UC-MS group and 29 patients in the placebo group.

539 § IL-6 values were available for 64 patients in the UC-MS group and 35 patients in the placebo group.

540 ¶ CRP values were available for 27 patients in the UC-MS group and 14 patients in the placebo group.

541 || The test results are summarized from hospitalization to the pre-random test. If there is any positive, it is defined as positive.

542 The IgG and IgM values were available for 63 patients in the UC-MS group and 34 patients in the placebo group.

543

14 **Table 2: Primary and secondary outcomes in the mITT population.**

	UC-MSc group (n = 65)	Placebo group (n = 35)	Difference
Change in the total lesion proportion (%) of the whole lung volume from baseline to day 28	-19.40(-53.40, -2.62)	-7.30(-46.59,19.12)	-13.31(-29.14,2.13) †
Change in solid component lesion proportion (%) of whole lung volume from baseline to day 28	-57.70(-74.95, -36.56)	-44.45(-62.24, -8.82)	-15.45(-30.82, -0.39) †
Change in ground-glass lesion proportion (%) of whole lung volume from baseline to day 28	-14.95(-51.55,7.29)	-3.94(-43.99,32.55)	-9.84(-30.51,6.86) †
6-minute walking distance at day 28 (meters) *	420.00 (392.00, 465.00)	403.00 (352.00, 447.00)	27.00 (0.00, 57.00) †
VCmax(L) at day 28 ¶	2.57 (2.13, 3.04)	2.49 (2.05, 2.76)	0.16 (-0.10, 0.43) †
DLco (L) at day 28	5.12 (1.62)	5.06 (1.57)	0.07 (-0.69, 0.82)
Six-category scale at day 10			0.77(0.33,1.79) &
1-Not hospitalised;	11(16.92%)	6(17.14%)	
2-Hospitalized, not requiring supplemental oxygen	8(12.31%)	6(17.14%)	
3-Hospitalized, requiring supplemental oxygen	44(67.69%)	23(65.71%)	
4-Hospitalized, on noninvasive ventilation or high flow oxygen devices	2(3.08%)	0(0.00%)	
Duration of oxygen therapy (days) ‡	22.00(13.00,32.00)	31.00(16.00,36.00)	-7.00(-17.00,3.00) †
Finger pulse oxygen in resting state (%) at day 28 §	97.10(1.31)	96.97(1.29)	0.13(-0.42,0.68)
mMRC dyspnea score at day 28 **			1.49(0.68,3.26) &
Grade 0 n(%)	29(47.54%)	13(37.14%)	
Grade 1 n(%)	24(39.34%)	16(45.71%)	
Grade 2 n(%)	5(8.20%)	4(11.43%)	
Grade 3 n(%)	3(4.92%)	1(2.86%)	
Grade 4 n(%)	0(0.00%)	1(2.86%)	

15 Data are median (interquartile range, IQR), mean (SD) or n (%).

16 * In the 6-minute walk test, there were three cases who could not complete the test because of cardiopulmonary function problems. The
17 data were calculated as 0 meters.

18 † Differences are expressed as Hodges-Lehmann estimator and 95% confidence interval (CI).

19 ¶ VCmax (L) at day 28 were available for 53 patients in the UC-MSc group and 31 patients in the placebo group.

20 || DLco (L) at day 28 were available for 53 patients in the UC-MSc group and 27 patients in the placebo group.

21 & Calculated by ordinal logistic regression model. OR=odds ratio.

22 ‡ Duration of oxygen therapy (days) were available for 29 patients in the UC-MSCs group and 11 patients in the placebo group.

23 § Finger pulse oxygen in resting state (%) at day 28 were available for 61 patients in the UC-MSCs group and 35 patients in the placebo
24 group.

25 ** mMRC dyspnea scores were available for 61 patients in the UC-MSCs group and 35 patients in the placebo group.

56 **Table 3. Summary of adverse events that occurred in the enrolled population of the trial.**

	UC-MSK group (n = 65)		Placebo group (n = 35)	
	Grade 1 or 2	Grade 3 or 4	Grade 1 or 2	Grade 3 or 4
Any adverse event	36 (55.38%)	1 (1.54%)	21 (60.00%)	0 (0.00%)
Increased lactic acid dehydrogenase	9(13.85%)	0(0.00%)	7(20.00%)	0(0.00%)
Increased alanine aminotransferase	7(10.77%)	0(0.00%)	4(11.43%)	0(0.00%)
Hypokalaemia	6(9.23%)	0(0.00%)	1(2.86%)	0(0.00%)
Increased aspartate aminotransferase	5(7.69%)	0(0.00%)	4(11.43%)	0(0.00%)
Increased serum uric acid	5(7.69%)	0(0.00%)	3(8.57%)	0(0.00%)
Diarrhoea	4(6.15%)	0(0.00%)	0(0.00%)	0(0.00%)
Palpitations	3(4.62%)	0(0.00%)	0(0.00%)	0(0.00%)
Increased γ -glutamyl transferase	2(3.08%)	0(0.00%)	1(2.86%)	0(0.00%)
Dizziness	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Cough	2(3.08%)	0(0.00%)	1(2.86%)	0(0.00%)
abdominal distention	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Anemia	2(3.08%)	0(0.00%)	0(0.00%)	0(0.00%)
Pneumothorax	0(0.00%)	1(1.54%)	0(0.00%)	0(0.00%)
Metabolic alkalosis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Urinary tract infection	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Bacterial infection	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pharyngitis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Increased heart rate	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Creatine phosphate stimulation	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Elevated blood urea	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Poor sleep quality	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Taste reversal	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Chest musculoskeletal	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pulmonary edema	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Pharyngeal diseases	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)

Anxious	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Nervous	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Rash	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Thirsty	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Nausea	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Countercurrent	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Non-infectious gingivitis	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Abdominal pain	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Functional gastrointestinal turbulence	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Vomit	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Gastroesophageal reflux disease	1(1.54%)	0(0.00%)	1(2.86%)	0(0.00%)
Toothache	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
heart failure	1(1.54%)	0(0.00%)	0(0.00%)	0(0.00%)
Hypocalcemia	0(0.00%)	0(0.00%)	2(5.71%)	0(0.00%)
Hepatic cyst	0(0.00%)	0(0.00%)	2(5.71%)	0(0.00%)
Creatine phosphate stimulation	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Elevated serum creatinine	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Respiratory alkalosis	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Pleural effusion	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Difficulty in falling asleep	0(0.00%)	0(0.00%)	1(2.86%)	0(0.00%)
Pruritus	0(0.00%)	0(0.00%)	3(8.57%)	0(0.00%)

Figure 1




Figure 1: Trial profile

ITT= intention-to treat population. mITT= modified intention-to treat population

Figure 2




Figure 2. Decline in total and solid component lesion proportion (%) between the MSC group and placebo group at 28 day.

- Panel A shows the between-group median difference in the change in total lesion proportion (%) and solid component lesion proportion (%) of the whole lung volume from baseline to day 28. I bars indicate the 95%CI described by Hahn and Meeker (1991).
- Panel B shows box plots of the change in the total lesion proportion (%) and solid component lesion proportion (%) of the whole lung volume from baseline to day 28. Q1 denotes the first quartile, and Q3 the third quartile. I bars indicate the minimum and maximum.
- Panel C shows the mean absolute change from baseline in the total lesion proportion (%) and solid component lesion proportion (%) of the whole lung volume. I bars indicate the standard error.